INSITE VISION SUBMITS NDA FOR AZASITE IN THE TREATMENT OF BACTERIAL CONJUNCTIVITIS WITH U.S. FDA

Thursday, InSite Vision, Inc., an ophthalmic products company, revealed the submission of a New Drug Application or NDA with the U.S. Food and Drug Administration for AzaSite indicated in the treatment of bacterial conjunctivitis. The submission includes positive results from the completed Phase 3 clinical trials, pre-clinical studies, chemistry, manufacturing, and controls.
Trading Markets Live